Health Canada Accepts Valneva s Chikungunya Vaccine License Application for Review tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
Saint-Herblain (France), August 29, 2023 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that Health Canada.
Valneva SE (VALN) reported positive initial Phase 3 safety data in adolescents for its single-dose chikungunya virus vaccine candidate VLA1553. The company said the initial safety data generated in the trial VLA1553-321 showed that VLA1553 was generally safe and well tolerated in adolescents aged 12 to 17 years, regardless of previous CHIKV infection.